伊普森公司的药物Elafibranor在治疗罕见的肝病原发性硬化性胆管炎方面表现有前途. Ipsen's drug Elafibranor shows promise in treating the rare liver disease primary sclerosing cholangitis.

伊普森的研究药物Elafibranor在治疗初级硬化性胆管炎 (PSC) 方面表现有前途,这是一种罕见的肝病,目前没有治疗方法. Ipsen's investigational drug Elafibranor shows promise in treating primary sclerosing cholangitis (PSC), a rare liver disease with no current treatments. 在欧洲生命体研究协会大会上提交的第二阶段ELMWOOD研究的数据表明,Elafibranor是安全和有效的,改善了肝功能并减少了诸如痒痒的症状。 Data from the Phase II ELMWOOD study presented at the European Association for the Study of the Liver (EASL) congress indicates Elafibranor is safe and effective, improving liver function and reducing symptoms like itching. 研究结果支持了对治疗多种肝脏疾病的药物的进一步研究。 The results support further research into the drug for treating multiple liver conditions.